{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T10:03:46Z","timestamp":1780308226448,"version":"3.54.0"},"reference-count":36,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2026,6,3]]},"DOI":"10.1080\/17474086.2026.2654720","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:04:42Z","timestamp":1775055882000},"page":"607-621","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Evolution of the European LeukemiaNet recommendations for chronic myeloid leukemia"],"prefix":"10.1080","volume":"19","author":[{"given":"Alkim","family":"Yolcu","sequence":"first","affiliation":[{"name":"Hacettepe University Faculty of Medicine","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Celalettin","family":"Haznedaroglu","sequence":"additional","affiliation":[{"name":"Hacettepe University Faculty of Medicine","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00048-4"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02664-w"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"issue":"5","key":"e_1_3_5_8_1","first-page":"1517","article-title":"An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American society of hematology","volume":"94","author":"Silver RT","year":"1999","unstructured":"Silver RT, Woolf SH, Hehlmann R, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American society of hematology. Blood. 1999;94(5):1517\u20131536.","journal-title":"Blood"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403006"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/shem.2003.50004"},{"issue":"4","key":"e_1_3_5_11_1","first-page":"513","article-title":"Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. an analysis by the chronic leukemia working party of the European group for blood and marrow transplantation (EBMT)","volume":"91","author":"Gratwohl A","year":"2006","unstructured":"Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. an analysis by the chronic leukemia working party of the European group for blood and marrow transplantation (EBMT). Haematologica. 2006;91(4):513\u2013521.","journal-title":"Haematologica"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11831"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-273979"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.833185"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.134"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-376087"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2914"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02341-4"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.7162"},{"issue":"4","key":"e_1_3_5_22_1","first-page":"215","article-title":"Generic imatinib mesylate is as effective as original glivec in the clinical management of CML","volume":"25","author":"Malkan UY","year":"2015","unstructured":"Malkan UY, Aksu S, Aktimur SH, et al. Generic imatinib mesylate is as effective as original glivec in the clinical management of CML. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI. 2015;25(4):215\u2013221.","journal-title":"UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.02.001"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw003"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17989"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.104"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0923"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-3775"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10010042"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-025-00598-8"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164175"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.769730"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.4081\/hr.2020.8950"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.102"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30087-0"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000745"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490003"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35953"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2026.2654720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:26:14Z","timestamp":1780305974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2026.2654720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,3]]}},"alternative-id":["10.1080\/17474086.2026.2654720"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2026.2654720","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}